DelveInsight’s, “Behçet’s Disease Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet’s Disease pipeline landscape. It covers Behçet’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Behçet’s Disease Pipeline Report

• DelveInsight’s Behçet’s Disease pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Behçet’s Disease treatment.
• The leading companies working in the Behçet’s Disease Market include AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Janssen Korea Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Hoffmann-La Roche, Bristol-Myers Squibb, Abott, Sanguine Biosciences, GlaxoSmithKline, and others.
• Promising Behcet’s Disease Pipeline Therapies in the various stages of development include Adalimumab, Veldona, Apremilast, Infliximab, Canakinumab, Pentoxifylline, TA-650, AIN457, Cytotoxic Combination, Abatacept, and others.
• August 2023: Amgen announced a study of Phases 3 Clinical Trials for Apremilast. The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet’s disease (BD) through week 12.
• August 2023: Ipekyolu Ilac Ltd. Sti announced a study of Phase 2 Clinical Trials for Pentoxifylline and Colchicine. Although Behçet’s Disease (BD) has no FDA-approved therapies, numerous clinical reports suggest that oral ulcers of BD may resolve when treated with systemic ingested pentoxifylline (PTX). The investigators here propose to investigate the therapeutic potential of PTX dissolved in muco-adherent formulation and directly applied to the oral lesions. This 60 patient proof of concept trial is designed to meet regulatory requirements for safety concerns while at the same time exploring the potential efficacy and clinical utility of this product. The investigators hypothesize that application of topical PTX will accelerate the healing of these lesions in a clinically meaningful way, and further hypothesize that topical PTX can become a valuable adjunct to any other systemic therapy for BD.

 

Request a sample and discover the recent advances in Behçet’s Disease Treatment Drugs @ Behçet’s Disease Pipeline Report

 

In the Behçet’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Behçet’s Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Behçet disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Behçet’s Disease Overview

Behcet disease was first described in 1937 by Hulusi Behçet from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum. Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology.

 

Find out more about Behçet’s Disease Therapeutics Assessment @ Behçet’s Disease Preclinical and Discovery Stage Products

 

Behçet’s Disease Emerging Drugs Profile

• Canakinumab: Novartis

 

Behçet’s Disease Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the Behçet’s Disease therapies. The Behçet’s Disease companies which have their Behçet disease drug candidates in the most advanced stage, i.e. Phase II include Novartis.

 

Learn more about the emerging Behçet’s Disease Pipeline Therapies @ Behçet’s Disease Clinical Trials Assessment

 

Scope of the Behçet’s Disease Pipeline Report

• Coverage- Global
• Behçet’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Behçet’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Behçet’s Disease Companies- AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Janssen Korea Ltd, Novartis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Hoffmann-La Roche, Bristol-Myers Squibb, Abott, Sanguine Biosciences, GlaxoSmithKline, and others.
• Behcet’s Disease Pipeline Therapies- Adalimumab, Veldona, Apremilast, Infliximab, Canakinumab, Pentoxifylline, TA-650, AIN457, Cytotoxic Combination, Abatacept, and others.

 

Dive deep into rich insights for new drugs for Behçet’s Disease Treatment, Visit @ Behçet’s Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Behçet disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Behçet disease– DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Canakinumab: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cipargamin: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. KPG612: Kangpu Biopharmaceuticals
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Behçet disease Key Companies
24. Behçet disease Key Products
25. Behçet disease- Unmet Needs
26. Behçet disease- Market Drivers and Barriers
27. Behçet disease- Future Perspectives and Conclusion
28. Behçet disease Analyst Views
29. Behçet disease Key Companies
30. 30.   Appendix

 

For further information on the Behçet’s Disease Pipeline therapeutics, reach out to Behçet’s Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking